Cycloproscaline

Cycloproscaline
Clinical data
Other namesCP; 4-Cyclopropoxy-3,5-dimethoxyphenethylamine; 4-cPrO-3,5-DMPEA
Routes of
administration
Oral
Drug classSerotonin receptor modulator; Serotonin 5-HT2A receptor agonist; Serotonergic psychedelic; Hallucinogen
ATC code
  • None
Pharmacokinetic data
Duration of action≥6 hours
Identifiers
  • 2-(4-cyclopropyloxy-3,5-dimethoxyphenyl)ethanamine
CAS Number
PubChem CID
ChemSpider
Chemical and physical data
FormulaC13H19NO3
Molar mass237.299 g·mol−1
3D model (JSmol)
  • COC1=CC(=CC(=C1OC2CC2)OC)CCN
  • InChI=1S/C13H19NO3/c1-15-11-7-9(5-6-14)8-12(16-2)13(11)17-10-3-4-10/h7-8,10H,3-6,14H2,1-2H3
  • Key:VRTSLAVKWTZKIT-UHFFFAOYSA-N

Cycloproscaline (CP), also known as 4-cyclopropoxy-3,5-dimethoxyphenethylamine (4-cPrO-3,5-DMPEA), is a psychedelic drug of the phenethylamine and scaline families related to mescaline. It is the homologue of mescaline in which the 4-methoxy group has been replaced with a 4-cyclopropoxy group. The drug has a dose of 60 mg or more orally and a duration of 6 hours or more, but has not been fully evaluated. It is a low-potency full agonist of the serotonin 5-HT2A receptor and also interacts with other serotonin receptors such as the serotonin 5-HT1A and 5-HT2C receptors. The drug's chemical synthesis has been described. Cycloproscaline was first described in the scientific literature by Daniel Trachsel and colleagues in 2013. Its pharmacology was studied in greater detail in 2021. The drug is not a controlled substance in Canada as of 2025.

See also